Sofosbuvir and daclatasvir combination therapy for current hepatitis C virus genotype 4 achieves SVR: a case report of HCV genotype 4 from the Amazon

Tarragô, Andréa Monteiro; Pereira, Grenda Leite; Victoria, Flamir da Silva; Marie, Adriana Malheiro Alle; Victoria, Marilu Barbieri

doi:10.1590/0037-8682-0094-2017

Cited by 1 publication

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most patients were infected with HCV genotype 1, followed by genotypes 3 and 2. In addition, the presence of genotype 4 [8] in our region as well as the presence of genotypes 1 and 2 in a single patient was observed. It is noted that most HCV patients had a <F2 grade of hepatic fibrosis according to the classification of the FIB-4 score.…”

Section: Resultsmentioning

confidence: 73%

Immunological Dynamics Associated with Direct-Acting Antiviral Therapies in Naive and Experimented HCV Chronic-Infected Patients

Pereira

Tarragô

Neves

et al. 2019

Mediators of Inflammation

Self Cite

View full text Add to dashboard Cite

The therapeutic strategies used in the treatment of hepatitis C are essentially based on the combination of direct-acting antiviral agents (DAAs). This therapy has been shown to be very effective in relation to patient adherence to treatment and has shown high rates of sustained virological response (SVR). However, the immunological dynamics of patients infected with HCV is poorly understood. This fact led us to investigate the immune system of naive and experienced patients, who we followed before the therapy and three months after the end of treatment. In this study, 35 naive and experienced Brazilian patients with chronic hepatitis C and 50 healthy donors (HD group) were studied. The analysis of the soluble immunological biomarkers was performed using the flow cytometry methodology. The SVR rate was >90% among the 35 patients. Before treatment, correlations in the naive HCV group demonstrated a mix of inflammatory response occurring with moderate correlations between chemokines, inflammatory cytokines, and Th2 profile, with a strong regulation between IL-10 and IL-17A. On the other hand, experienced patients demonstrated a poor interaction between cytokines, chemokines, and cells with a strong correlation between IL-10, IL-6, CXCL-10, and CD8+ besides the interactions between IFN-γ and IL-4. Furthermore, naive and experienced patients seem to have a distinct soluble biomarker profile; therefore, a long-term follow-up is needed to evaluate patients treated with DAAs.

show abstract

Section: Resultsmentioning

confidence: 73%